[Articles] Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

AI Summary

Ralinepag, an oral prostacyclin-pathway drug, significantly reduces the risk of clinical worsening in pulmonary arterial hypertension patients on background therapy but shows a higher rate of adverse-event-related discontinuations. These findings support its use as an effective treatment option for PAH.

In patients with PAH receiving contemporary background therapy, ralinepag significantly reduced the risk of first clinical worsening compared with placebo, but was associated with more adverse-event-related treatment discontinuations. These results support the use of ralinepag as an oral, once-daily prostacyclin-pathway treatment option for PAH.